Talia Golan

Research interests

Publications

• Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

  Annals of Oncology · 2023 · https://doi.org/10.1016/j.annonc.2023.08.009

• Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer

  Journal of Clinical Oncology · 2022 · https://doi.org/10.1200/jco.21.01604

• A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer

  ESMO Open · 2022 · https://doi.org/10.1016/j.esmoop.2022.100639

• Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma

  Gastroenterology · 2021 · https://doi.org/10.1053/j.gastro.2021.01.220

• Homologous Recombination Deficiency in Pancreatic Cancer: A Systematic Review and Prevalence Meta-Analysis

  Journal of Clinical Oncology · 2021 · https://doi.org/10.1200/jco.20.03238

• The human tumor microbiome is composed of tumor type–specific intracellular bacteria

  Science · 2020 · https://doi.org/10.1126/science.aay9189

• BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial

  Nature Medicine · 2020 · https://doi.org/10.1038/s41591-020-0880-x

• Integration of Genomic and Transcriptional Features in Pancreatic Cancer Reveals Increased Cell Cycle Progression in Metastases

  Cancer Cell · 2019 · https://doi.org/10.1016/j.ccell.2018.12.010

• Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study

  Gastric Cancer · 2019 · https://doi.org/10.1007/s10120-018-00909-5

• Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer

  New England Journal of Medicine · 2019 · https://doi.org/10.1056/nejmoa1903387

• Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer

  JAMA Oncology · 2018 · https://doi.org/10.1001/jamaoncol.2018.0013

• KEYNOTE-059 cohort 1: Efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer.

  Journal of Clinical Oncology · 2017 · https://doi.org/10.1200/jco.2017.35.15_suppl.4003

• Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine

  Science · 2017 · https://doi.org/10.1126/science.aah5043

• Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial

  The Lancet Oncology · 2016 · https://doi.org/10.1016/s1470-2045(16)00175-3

• Identification of tissue-specific cell death using methylation patterns of circulating DNA

  Proceedings of the National Academy of Sciences · 2016 · https://doi.org/10.1073/pnas.1519286113

• RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients

  Oncotarget · 2015 · https://doi.org/10.18632/oncotarget.4183

• Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers

  British Journal of Cancer · 2014 · https://doi.org/10.1038/bjc.2014.418

• Mutant KRAS is a druggable target for pancreatic cancer

  Proceedings of the National Academy of Sciences · 2013 · https://doi.org/10.1073/pnas.1314307110

Current projects

No projects listed.